There are 2867 resources available
Toxicities of CAR T cell and bispecific
Presenter: Claire Roddie
Session: Emerging toxicities of new anticancer therapies
Resources:
Slides
Webcast
1321MO - Relevance index by cancer type: Trends and regional variation analysis, 2016-2020, Republic of Korea
Presenter: jeehee pyo
Session: Mini Oral session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1644O - Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION)
Presenter: Yansong Lin
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
458MO - Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)
Presenter: Joline Lim
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA10 - Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
Presenter: Melissa Johnson
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
LBA11 - IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
Presenter: Siow Ming Lee
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
Discussion: How to design better trial taking into account toxicities
Presenter: All Speakers
Session: Emerging toxicities of new anticancer therapies
Resources:
Webcast
1322MO - Selection of a set of quality indicators (QIs) on the care pathway in onco-hematology using a panel of experts
Presenter: Mario di Palma
Session: Mini Oral session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1645O - Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
Presenter: Jaume Capdevila Castillon
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 457MO and 458MO
Presenter: Irene Brana
Session: Mini Oral session: Developmental therapeutics
Resources:
Slides
Webcast